Monday, May 20, 2013 1:05:28 PM
NanoViricides, Inc
Symbol: NNVC
Current Price: $.55
52 Week Range: .32- $81
Read: www.nanoviricides.com/
Read: finance.yahoo.com/q?s=nnvc&ql=1
ABOUT THE COMPANY: NNVC-
NanoViricides, Inc. (NNVC)
is a development stage, publicly traded,
fully reporting company (symbol: NNVC).
It has developed a unique
nanomedicine-based approach to
develop novel anti-viral agents.
A NanoViricide™ is a specially designed,
flexible, anomaterial that may contain an
encapsulated active pharmaceutical
ingredient and is specifically targeted t
o a specific
type of virus, like a guided missile.
NanoViricide drugs are designed to
block and
dismantle the virus particles before
they can infect a cell,
thereby controlling viremia.
Drugs in Development
Pre-Clinical Studies:
Drugs Currently Nearing IND Status:
1.Dengue Antiviral/DengueCide
2.HivCide for treatment of HIV and AIDS
3.FluCide
Drugs Currently in Pre-clinical testing:
1.Dengue Antiviral (UC Berkeley, Dr. Eva Harris)
2.HIV-Cide (UCSF)
3.FluCide for HxNx (H1N1 Swine Flu, H5N1 Avi Flu, etc) (SRI, Thevac)
4.EKC/Eye Herpes (Thevac, Feinstein Institute)
5.HSV-1 and HSV-2 antiviral (NOUCM, Dr Ken S. Rosenthal)
6.EbolaCide for Ebola (USAMRIID)
Future Studies Planned and in Development by NNVC:
Marburg
Rift Valley Fever
West Nile Fever
Junin virus
Machupo virus
Lassa Fever
Hanta Virus
CMV Eye
Hepatitis B & C
Chukungunya Fever
Delivery Methods for a nanoviricide:
•Injectables
•Bronchial Sprays
•Nasal Sprays (Nose Drops)
•Ocular (Eye Drops)
•Oral for special circumstances
•Skin Patches
If you are looking for a stock with big
upside potential, and a great story,
NNVC might be just what you
are looking for!
Trade Well,
Stock Professors
followed by boiler plate disclaimer.
gch
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM